Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation.
Peter A DeRosaKyle C RocheVictor E NavaSunita SinghMin-Ling LiuAnita AgarwalPublished in: Current oncology (Toronto, Ont.) (2022)
Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with somatic mutation (L265P) of myeloid differentiation primary response 88 gene ( MYD88 ) in 80-90%, or various mutations of C-terminal domain of the C-X-C chemokine receptor type 4 ( CXCR4 ) gene in 20-40% of cases. A unique, progressive case of concurrent MDS and WM with several somatic mutations (some unreported before) and a novel balanced reciprocal translocation between chromosomes 10 and 13 is presented below.
Keyphrases
- bone marrow
- copy number
- diffuse large b cell lymphoma
- genome wide
- dendritic cells
- acute myeloid leukemia
- locally advanced
- mesenchymal stem cells
- oxidative stress
- multiple sclerosis
- genome wide identification
- multiple myeloma
- radiation therapy
- cell cycle arrest
- inflammatory response
- transcription factor
- rectal cancer
- cell migration